Complete Guide to mRNA-3927 Pharmacokinetics
Overview
mRNA-3927 is a mRNA-LNP used in the Rare Disease therapeutic area. It is indicated for Propionic Acidemia. PK/PD simulator for mRNA-3927 in propionic acidemia. Moderna gene therapy for metabolic enzyme replacement.
Mechanism of Action
mRNA-3927 exerts its pharmacological effect by targeting PCCA/PCCB. As a mRNA-LNP, it modulates this target to achieve therapeutic efficacy in Propionic Acidemia. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PK/PD models for mRNA-3927:
| Parameter | Value |
|---|---|
| LNP CL | rapid (t½ ~0.5-2 h plasma) |
| dose range | 0.1-0.5 mg/kg IV q2w or q3w |
| protein Tmax | 6-24 h |
| 2-MC reduction | biomarker of efficacy |
| hepatic uptake | primary organ |
| protein duration | ~7-14 days |
| PCC restoration target | >5% normal |
| mRNA intracellular t half | 6-15 h |
| PCC enzyme activity baseline | <1% (PA patients) |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
mRNA-3927 is administered via the IV route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Rare Disease therapeutic area, for the treatment of Propionic Acidemia, understanding the pharmacokinetics of mRNA-3927 is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect mRNA-3927 pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive mRNA-3927 PK Simulator
Explore mRNA-3927 pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of mRNA-3927?
The elimination half-life of mRNA-3927 depends on patient-specific factors. Use our interactive mRNA-3927 PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is mRNA-3927 administered?
mRNA-3927 is administered via the IV route. It is indicated for Propionic Acidemia. As a mRNA-LNP, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of mRNA-3927?
Key pharmacokinetic parameters for mRNA-3927 include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate mRNA-3927 dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive mRNA-3927 PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.